Oral Session 1-7A Malignant Lymphoma: Clinical Trials

[OS1-7A-6] PF-05280586 (a proposed rituximab biosimilar) for follicular lymphoma: subgroup analyses

Naohiro Sekiguchi¹, Toshiki Uchida², Shinsuke Wada³, Shintaro Hiro³, Kei Fukuhara³, Kentaro Tajima⁴, Kenichi Ishizawa⁵ (1.National Hospital Organization Disaster Medical Center, Tokyo, Japan, 2.Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan, 3.Pfizer R&D Japan, Tokyo, Japan, 4.Pfizer Japan Inc., Tokyo, Japan, 5.Yamagata University Faculty of Medicine, Yamagata, Japan)